USPTO Allows Lantern Pharma's LP-284 Method Patent for Aggressive B-Cell Lymphomas
LTRN sits 33% above its 52-week low of $1.11.
Summary
Lantern Pharma received a USPTO Notice of Allowance for a method-of-treatment patent covering LP-284 in mantle cell lymphoma, double-hit lymphoma, and other blood cancers. The allowed claims include monotherapy and combination use with several drug classes, plus intravenous and intraperitoneal delivery. This extends LP-284's IP protection to 2042, building on existing composition-of-matter patents. The news strengthens the commercial outlook for LP-284, which is in Phase 1 trials and has shown a complete metabolic response in a heavily pretreated DLBCL patient. The company faces a going concern warning, so this patent milestone is a meaningful positive for its lead asset.
At the time of this announcement, LTRN was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.2M. The 52-week trading range was $1.11 to $4.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.